Dr Drilon on the Potential Benefit of Taletrectinib in ROS1+ NSCLC

Alexander Drilon, MD, discusses the potential benefit of taletrectinib in patients with ROS1-positive non–small cell lung cancer.

Related Keywords

China ,Alexander Drilon ,Repotrectinib Augtyro ,Memorial Sloan Kettering Cancer Center ,Advances In Precision Medicine Lung Cancer ,Onclive Tv ,Lung Cancer ,Publications ,